Vioxx GMP Violations Cited In FDA Warning Letter Spur Merck Retraining

Inadequate sampling, testing, investigation and documentation of Merck's Vioxx (rofecoxib) lots are among good manufacturing practice violations cited in a June 27 FDA warning letter.

Inadequate sampling, testing, investigation and documentation of Merck & Co. Inc.'s Vioxx (rofecoxib) lots are among good manufacturing practice violations cited in a June 27 FDA warning letter.

"Two lots of rofecoxib pure were released for distribution despite analytical findings that they were contaminated with polypropylene fibers in...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet